Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro.
A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results.
NOVANTRONE. mitoXANTRONE for injection concentrate
Molecular characterization of a peripheral receptor for cannabinoids.
Interferon-β-1b: a review of its use in multiple sclerosis.
Receptos to initiate Phase 3 trial of RPC1063 in relapsing multiple sclerosis
Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid.
Glatiramer acetate (GA) prevents TNF-α-induced monocyte adhesion to primary endothelial cells through interfering with the NF-κB pathway.
Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid communication.
Flupirtine
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development.
Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
CCR2 defines in vivo development and homing of IL-23-driven GM-CSF-producing Th17 cells.
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial.
Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?
PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients
Progressive Multifocal Leukoencephalopathy: Why Gray and White Matter.
Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function.
Merck: Regulatory Update on Cladribine Tablets
Gray matter SWI-filtered phase and atrophy are linked to disability in MS .
Masitinib is being investigated in the treatment of amyotrophic lateral sclerosis (ALS)
199 Outcomes after microvascular decompression for patients with trigeminal neuralgia and suspected multiple sclerosis.
Study of teriflunomide in reducing the frequency of relapses and accumulation of disability in patients with multiple sclerosis (TEMSO)

Pages